MN1 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q10571 |
---|---|
Clone Names | 100324066 |
Gene ID | 4330 |
---|---|
Other Names | Probable tumor suppressor protein MN1, MN1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | MN1 |
---|---|
Function | Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable). |
Cellular Location | Nucleus. |
Tissue Location | Widely expressed in fetal and adult tissues. Highest expression is observed in fetal brain and skeletal muscle, and adult skeletal muscle. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Meningioma 1 (MN1) contains two sets of CAG repeats. It isdisrupted by a balanced translocation (4;22) in a meningioma, andits inactivation may contribute to meningioma 32 pathogenesis.
References
Liu, T., et al. Leukemia 24(3):601-612(2010)Kandilci, A., et al. Blood 114(8):1596-1606(2009)Trynka, G., et al. Gut 58(8):1078-1083(2009)Langer, C., et al. J. Clin. Oncol. 27(19):3198-3204(2009)Schroeder, T., et al. Leuk. Lymphoma 50(6):1043-1046(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.